An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers

por Elishmereni, Moran, Kheifetz, Yuri, Søndergaard, Henrik, Overgaard, Rune Viig, Agur, Zvia
Publicado 2011

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials

por Juul, Rasmus Vestergaard, Rasmussen, Michael Højby, Agersø, Henrik, Overgaard, Rune Viig
Publicado 2018

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan

por Juul Kildemoes, Rasmus, Højby Rasmussen, Michael, Agersø, Henrik, Overgaard, Rune Viig
Publicado 2020

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach

por Papathanasiou, Theodoros, Strathe, Anders, Agersø, Henrik, Lund, Trine Meldgaard, Overgaard, Rune Viig
Publicado 2020

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

por Carlsson Petri, Kristin Cecilie, Ingwersen, Steen Hvass, Flint, Anne, Zacho, Jeppe, Overgaard, Rune Viig
Publicado 2018